Ignite Creation Date:
2024-05-06 @ 6:07 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05544240
Status:
RECRUITING
Last Update Posted:
2024-05-03
First Post:
2022-08-16
Brief Title:
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With AdvancedMetastatic Solid Tumors
Sponsor:
Williams Cancer Foundation
Organization:
Williams Cancer Foundation
Study Overview
Official Title:
Phase 1 Trial of SYNC-T - Immunotherapy Regimen Given After Controlled Cellular Lysis for Patients With AdvancedMetastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None